1                                                At 52 weeks, we noted no significant difference between groups for disease

2 ns than the group without (IDR 1.39 [95% CI 1.07-1.79]) and we noted no significant difference between groups in readmiss

3                                                             We noted no significant differences between groups for total

4 r for IDeg 3TW(AM) than for IGlar OD (ERR 2.12, 1.08-4.16); we noted no significant difference between IDeg 3TW(PM) and I

5                                                             We noted no significant differences between individuals in th

6                                                             We noted no significant differences between statin users and

7               187 (57%) experienced no discontinuities, and we noted no significant difference between the CTO and contro